Affiliation:
1. Alkaloid AD, blv. Aleksandar Makedonski No. 12, 1000 Skopje, Republic of Macedonia
2. Novo Nordisk Farma dooel, str. Nikola Kljusev No. 11, 1000 Skopje, Republic of Macedonia
Abstract
Pharmacoeconomics is new and modern health science, implemented in developed societies, to play core role in creating health policies. The main aim of pharmacoeconomic analysis is development of science methodology for evaluation of costs and outcomes of treatment, evaluation of economic parameters in the face of outcomes of clinical results, from different treatment options. Pharmaceutical companies implemented pharmacoeconomic principles for diversifying marketing approach and market access in pharmaceutical development. New healthcare systems demand increased costs for medical care, pharmaceutical products and medical devices. Process of medical costs for evaluation of costs evolved, indirect and hidden costs are part of sole process of evaluation. Health authorities from one side and pharmaceutical companies from other side developed unique methodologies for evaluation. With these implemented changes, traditional concept for evaluation of efficacy and safety of medical devices and pharmaceutical products was overbridged and pharmacoeconomics is base for research, development, registration, reimbursement, as well as dispensing and follow the life cycle of medicines. Results from antibiotic consumption analysis in Republic of Macedonia at 2016 showed that total antibiotic consumption and antibiotic consumption per DDD/1000 citizens is according to average EU trends, mostly similarly to the usage trends of low-income countries. But usage of new and innovative antibiotic is on very low level, which indicates the need of further implementing of pharmacoeconomic analysis and principles in decision making process, for improved health care for the patients. The ultimate goal of implementing the pharmacoeconomic system in each country is enhancing the benefit to the patient through improved resource allocation.
Keywords: pharmacoeconomics, type of pharmacoeconomic analysis, antibiotic consumption, Republic of Macedonia
Publisher
Macedonian Pharmaceutical Association
Reference23 articles.
1. Acevski, S., Minov, J., Sterjev, Z., Zareski, R., Kapedanovska Nestorovska, A., Suturkova, Lj., 2016. Cost Effectiveness Analysis of Antibiotic Regimens Used inOutpatient Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Adv. Pharmacoepidemiol. Drug Saf. 5, 212. Available at: https://doi.org/10.4172/2167-1052.1000212.
2. Annual Report for 2016. Health Insurance Fund of Republic of Macedonia, available at: http://www.fzo.org.mk. Last accessed: January 22, 2018.
3. Cairns, J., 1996. Measuring health outcomes. BMJ 313(7048), 6.
4. Drummond, M., 1992. Cost-of-illness studies. Pharmacoeconomics 2(1), 1-4. Available at: https://doi.org/10.1136/bmj.320.7245.1335.
5. Drummond, M., 1994. Economic analysis alongside controlled trials: an introduction for clinical researchers. London: Department of Health.